Cis-interaction network of PD-L1 and its impact on anti-cancer immunotherapy
DOI：10.3872/j.issn.1007-385x.2020.12.01
- VernacularTitle:PD-L1顺式互作网络及其对抗肿瘤免疫治疗的影响
- Author:
BAI Rilan
1
;
GUO Hanfei
1
;
CUI Jiuwei
1
Author Information
1. Cancer Center, the First Hospital of Jilin University, Changchun 130021, Jilin, China
- Publication Type:Journal Article
- Keywords:
tumor;
immune checkpoint;
cis-interaction;
programmed death ligand-1;
soluble CD80 protein
- From:
Chinese Journal of Cancer Biotherapy
2020;27(12):1313-1318
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] In recent years, investigation on immune checkpoint inhibitors has made exciting progress in anti-tumor therapy. Through continuous exploration, there is a deeper understanding of intermolecular interaction patterns among PD-L1, PD-1, CD80, CTLA-4, etc. In addition to classically acting as a T cell inhibitory receptor, PD-L1 was found to be co-expressed with PD-1 or CD80 on the same cell and play a positive immunoregulatory function through cis-interaction, significantly affecting the interaction network between tumor cells and immune cells and the efficacy of immunotherapy, and bringing new changes to the understanding of the mechanisms of cancer immunotherapy. This review provides an in-depth analysis of the cis-PD-L1/PD-1 and cis-PD-L1/CD80 pathways and their interactions with a complex network of CTLA-4 and CD28 molecules, finally outlines the effects of blocking this cis-interaction pathway on T cell signaling, cytotoxic function, and the efficacy of anti-tumor immunotherapy.
- Full text:20201201.pdf
